



H1 2026 – Preliminary Unaudited Revenue

*SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION,
AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES*



31 July 2026

Disclaimer

This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at <https://www.medacta.com/EN/investors>.

FORWARD-LOOKING INFORMATION

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions. There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group

operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

ALTERNATIVE PERFORMANCE MEASURES

This Presentation may contain information regarding alternative performance measures. Definitions of these measures may be found on the financial reports available on our website at <https://www.medacta.com/EN/investors>.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP

Related Trademarks

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, MyKA™, NextAR™, NextAR™ Spine.

Not all products are available in all countries. Product availability is dependent upon the registration requirements for your country. All trademarks and registered trademarks are the property of their respective owners.



FRANCESCO SICCARDI

Chief Executive Officer



Continuing to outperform market in H1 2026

H1 2026 revenue in EUR*

368 m

H1 2026 revenue growth*

9.7 % in c.c.**

7.0 % in EUR

Two major expansion projects

- *Construction work in Ticino (CH) advancing; building shell already completed*
- *Acquisition of land for expansion and development of new manufacturing capacity in the US*

Outlook 2026 confirmed

Targeting a revenue growth in the range of 10% to 14% in c.c. and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in c.c.*, subject to unforeseen events*

Mid-term outlook confirmed

Revenue CAGR (2024–2027E) in c.c. is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in c.c.*, subject to unforeseen events*

Medacta's success pillars for above-market growth

1

Differentiating innovations

*with aim to improve patient outcomes
& healthcare sustainability*

2


Education and personalized training of surgeons

*thereby acquiring new surgeons
across all business lines*


3

Team expansion


*to increase network of surgeons
& foster further growth*



Outgrowing market in all geographies




H1 2026 geographic revenue distribution




- APAC and EMEA continuing to deliver double-digit revenue growth
- NORAM: growing above market despite some temporary softening in Joints and Spine, the latter due to a sales channel transition
- LATAM: advancing in mid-teens following a strong stock purchasing of new distributors in the previous year


Excellent above-market growth across all business lines



H1 2026 revenue distribution by business line



Continued strong performance in Hip



Hip – H1 2026

- First cases with NextAR Hip in the U.S. and Australia completed
- Outstanding growth in APAC and LATAM
- Around 1.8 x above-market growth 2026** yoy



AMIS[®] Experience
 ANTERIOR MINIMALLY INVASIVE SURGERY
 IN HIP REPLACEMENT



#beMedacta |

● TRUST AND
INTEGRITY

● EFFICIENT
EXECUTION

● PATIENT AND
CUSTOMER FOCUSED

● SUSTAINABLE
INNOVATION


● TEAMWORK

Notes

* In constant currency

** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2026

Further notable expansion in Knee




Knee – H1 2026

- GMK SpheriKA and Efficiency single use instruments continue to find increasing adoption with surgeons
- Continued double-digit growth in APAC and EMEA
- 2.1x above-market growth 2026E** yoy




Solid growth in Spine



Spine – H1 2026

- Launch of NextAR Spine 2.0
- Continued strong performance in EMEA, followed by LATAM and APAC
- 1.4x above-market growth 2026E** yoy

Continued robust growth in Extremities



Extremities – H1 2026

- Successful completion of first U.S. revision shoulder arthroplasty with NextAR Shoulder, supported by the new AI based MyShoulder Planner for advanced preoperative 3D planning
- Sportsmed launched SecureFix™ All-Inside Meniscal Repair System for knee sports medicine offering distinguished ease of use
- More than 2x above-market growth 2026E** yoy in Extremities

Outlook

Outlook 2026

Medacta is targeting a revenue growth in the range of 10% to 14% in constant currency and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in constant currency, subject to unforeseen events.

Mid-term outlook

Revenue compound annual growth rate (CAGR) (2024–2027E) in constant currency is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in constant currency, subject to unforeseen events.

Tariffs

Medacta remains not impacted by the US tariffs and will continue to monitor the development.

Key messages

Continued above-market growth as result of

- *Differentiating innovations to improve patient outcomes and healthcare sustainability*
- *Education and personalized training of surgeons*
- *Further expansion of sales reps and team*

Our aim

- *To continue to outgrow the market*

Thank you

to all our employees, clients, suppliers and partners worldwide



MEDACTA.COM
